Rigontec is a leading company in the immune-oncology field developing compounds interacting with RIH-I receptor. The company was acquired August 2017 by MSD for up to EUR 463 million.
Location: Germany, Bavaria, Planegg
Total raised: $16.88M
Investors 1
| Date | Name | Website |
| - | Forbion | forbion.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.09.2016 | Series A | $16.88M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 07.09.2017 | Term Sheet — Thursday, September 7 | SPORTS TALK Good morning, Term Sheet readers. Paid Content What you need to know about growing cyb... | fortune.co... |
| 06.09.2017 | MSD to acquire Rigontec | MSD today announced the acquisition of Rigontec for up to US$553M | wellington... |
| 03.05.2017 | Rigontec starts FIH Phase I/II trial of RIG-I agonist RGT100... | Rigontec today announced the dosing of the first patient in a phase I/II study with intratumoral/int... | wellington... |
| 14.11.2016 | Rigontec appoints new CSO | Rigontec Appoints Dr. Jörg Vollmer as Chief Scientific Officer | wellington... |
| 06.09.2016 | Rigontec Raises Additional €15M in Extended Series A to Adva... | Rigontec, the leader in RIG-I targeting RNA therapeutics, today announced that it has secured EUR 15... | forbion.co... |
| - | Rigontec Raises Additional €15M in Extended Series A to Adva... | September 6, 2016 Rigontec, the leader in RIG-I targeting RNA therapeutics, today announced that it... | htgf.de/en... |